Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

被引:24
|
作者
Dietrich, Sascha [1 ]
Radujkovic, Aleksandar [1 ]
Stoelzel, Friedrich [2 ]
Falk, Christine S. [3 ]
Benner, Axel [4 ]
Schaich, Markus [2 ]
Bornhaeuser, Martin [2 ]
Ehninger, Gerhard [2 ]
Kraemer, Alwin [1 ]
Hegenbart, Ute [1 ]
Ho, Anthony D. [1 ]
Dreger, Peter [1 ]
Luft, Thomas [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Internal Med 5, D-69120 Heidelberg, Germany
[2] Tech Univ Dresden, Dept Internal Med 1, Univ Hosp Carl Gustav Carus Dresden, Dresden, Germany
[3] Hannover Med Sch, Inst Transplant Immunol, IFB Tx, Hannover, Germany
[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
关键词
BODY-MASS INDEX; VERSUS-HOST-DISEASE; MYELODYSPLASTIC SYNDROME; RISK-FACTORS; WEIGHT-LOSS; SURVIVAL; OVERWEIGHT; CHILDREN; AML; NUTRITION;
D O I
10.1097/TP.0000000000000471
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The impact of nutritional status on outcome of allogeneic stem cell transplantation (alloSCT) is controversial. This study investigates the influence of pretransplant weight loss and serologic indicators of nutritional homeostasis on relapse and death of acute myeloid leukemia (AML) after alloSCT. Methods. Pretransplant weight loss along with serum levels of total serum protein (TSP), albumin, C-reactive protein, and leptin were collected retrospectively in a training cohort (n = 149) and correlated with clinical outcome. Metabolic risk groups were defined and tested in an independent validation cohort (n = 167). Results. We identified pretransplant weight loss and TSP as strong independent predictors of relapse and death. Patients in the metabolic high-risk group (low TSP and weight loss) had an increased risk for relapse (P = 0.0002) and death (P = 0.002), but a similar risk for acute graft-versus-host disease. Weight loss coincided with reduced pretransplant serum leptin levels. The adverse influence of weight loss and high metabolic risk on relapse and overall survival could be confirmed in the validation cohort and similarly in patients with less than or more than 5% blasts before alloSCT. Multivariate analysis of both cohorts revealed a hazard ratio for relapse of 7.78 (2.59-23.36, P = 0.0003) in the metabolic high risk group. Conclusion. Altered nutritional homeostasis before alloSCT correlates with recurrence of AML after transplantation. Studies addressing pretransplant nutritional interventions to reduce AML relapse rates are warranted.
引用
收藏
页码:1065 / 1071
页数:7
相关论文
共 50 条
  • [1] Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
    Facenda-Lorenzo, Maria
    Sanchez-Quintana, Ana
    Quijada-Fumero, Alejandro
    Laynez-Carnicero, Ana
    Brena-Atienza, Joaquin
    Poncela-Mireles, Francisco J.
    Llanos-Gomez, Juan M.
    Cabello-Rodriguez, Ana I.
    Ramos-Lopez, Maria
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2016, 2016
  • [2] Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation
    Oran, Betul
    de Lima, Marcos
    [J]. CURRENT OPINION IN HEMATOLOGY, 2011, 18 (06) : 388 - 394
  • [3] Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
    Fathi, Amir T.
    Chen, Yi-Bin
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (02) : 186 - 192
  • [4] Extramedullary Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
    Yuda, Sayako
    Fuji, Shigeo
    Tanaka, Yosuke
    Kawajiri, Akihisa
    Ozawa, Takayuki
    Hirakawa, Tsuneaki
    Onishi, Akio
    Tanaka, Takashi
    Inamoto, Yoshihiro
    Kurosawa, Saiko
    Kim, Sung-Won
    Yamashita, Takuya
    Tanosaki, Ryuji
    Fukuda, Takahiro
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S215 - S215
  • [5] Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
    Amir T. Fathi
    Yi-Bin Chen
    [J]. Current Hematologic Malignancy Reports, 2014, 9 : 186 - 192
  • [6] DECITABINE TREATMENT FOR ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Liu, X-L.
    Zhao, X.
    Wang, C.
    Gao, S-J.
    Tan, Y-H.
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2017, 31 (01): : 171 - 175
  • [7] Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
    Rautenberg, Christina
    Germing, Ulrich
    Haas, Rainer
    Kobbe, Guido
    Schroeder, Thomas
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (01)
  • [8] Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
    Koenecke, Christian
    Kuempers, Philipp
    Lukasz, Alexander
    Hecker, Hartmut
    Dammann, Elke
    Verhagen, Willem
    David, Sascha
    Goehring, Gudrun
    Buchholz, Stefanie
    Weissinger, Eva
    Krauter, Juergen
    Eder, Matthias
    Haller, Hermann
    Ganser, Arnold
    [J]. BLOOD, 2008, 112 (11) : 1119 - 1119
  • [9] Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia
    Huisman, C.
    De Weger, R. A.
    de Vries, L.
    Tilanus, M. G. J.
    Verdonck, L. F.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 (05) : 285 - 291
  • [10] Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia
    C Huisman
    R A de Weger
    L de Vries
    M G J Tilanus
    L F Verdonck
    [J]. Bone Marrow Transplantation, 2007, 39 : 285 - 291